The research peptide vendor landscape in the USA changed dramatically between mid-2025 and mid-2026. At least nine major vendors closed in a twelve-month period, including three of the most recognized names in the industry. Peptide Sciences, the largest USA research peptide vendor by volume, shut down voluntarily on March 6, 2026. Amino Asylum was raided by the FDA in June 2025. Paradigm Peptides saw its founders plead guilty to federal charges in December 2025, with founder Matthew Kawa sentenced to 70 months in federal prison and a $5 million forfeiture in July 2026.
For USA researchers who relied on these vendors, the closures were disruptive. Orders were unfulfilled. Batch documentation went offline. Supply chains were interrupted mid-protocol. The researchers searching for the best peptide company in the USA in 2026 are not starting from scratch. They are experienced buyers who know exactly what they need and are evaluating remaining compliant vendors against a much higher bar than existed two years ago.
This guide explains what happened, what it means for sourcing research compounds going forward, and what specific criteria separate a trustworthy compliant supplier from the grey-market model that collapsed.
What Happened to the Research Peptide Market in 2025 and 2026?
Understanding the vendor collapses requires understanding the regulatory escalation that preceded them. The FDA did not suddenly change its approach. The enforcement timeline shows a gradual but accelerating escalation from administrative action to criminal prosecution.
The FDA Enforcement Timeline
In December 2024, the FDA issued warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research for selling unapproved drug products. These were administrative actions, the traditional FDA tool for addressing non-compliance in the research peptide space.
The escalation changed significantly in June 2025 when FDA agents physically raided the Amino Asylum warehouse in Texas, seizing inventory and records and shutting down operations overnight. This was the first physical raid on a major peptide vendor and represented a qualitative shift from letters to enforcement action. In September 2025, the FDA issued more than fifty warning letters in a single month targeting GLP-1 compounding pharmacies producing semaglutide and tirzepatide copies.
In December 2025, the Paradigm Peptides case concluded with guilty pleas. The investigation revealed that Paradigm had been selling products labeled as SARMs that actually contained testosterone, a controlled substance, over conduct running from 2019 to 2024. This was not a grey-area compliance issue. It was deliberate product adulteration with a controlled substance.
On March 6, 2026, Peptide Sciences posted a three-sentence notice and stopped accepting orders. No official explanation was provided beyond the word “voluntary.” By March 2026, the pattern was clear: the grey-market research-use-only model faced mounting enforcement risk and vendors operating in compliance grey areas were calculating their exits.
Why This Matters for Researchers
The combined effect of these closures is that the number of USA-based research peptide vendors with verifiable quality infrastructure has contracted significantly. This is not necessarily a negative development for the research community. The vendors that closed were, in most cases, operating with insufficient quality controls, inadequate documentation, or in the case of Paradigm Peptides, outright product fraud.
The FDA testing data that underpins the enforcement wave is illuminating. Testing found that 40% of online research peptide products contained incorrect dosages and 25% contained compounds not listed on the label. These are not edge cases. They represent widespread quality failures across a significant portion of the market.
For researchers, this data reframes the vendor selection question entirely. The question is not which vendor has the best prices or the widest catalog. The question is which vendor can demonstrate that what is in the vial is what is on the label.
What to Look for in the Best Peptide Supplier in 2026
The vendor collapses of 2025 and 2026 have created a clear framework for evaluating research peptide suppliers. Every criterion below directly addresses the specific failure modes that caused vendor shutdowns or quality problems.
Batch-Specific Third-Party COA Documentation
This is the single most important criterion and the one that most directly addresses the FDA contamination finding. A certificate of analysis from an independent third-party laboratory, covering a specific production batch with HPLC purity data and mass spectrometry identity confirmation, is the minimum acceptable documentation for any research compound purchase in 2026.
The critical word is independent. A COA generated by the vendor’s own facility is not independent verification. The laboratory named on the COA must be a separate entity from the supplier. Fine Research Peptides provides independent third-party COA documentation for every compound on our lab certifications page before you place your order.
Domestic USA Shipping and Transparent Operations
Vendors operating from domestic USA facilities with verifiable contact information and transparent business practices carry a fundamentally different risk profile from overseas or semi-anonymous operations. Domestic shipping also protects compound integrity during transit by eliminating international temperature excursion risk.
Fine Research Peptides ships all orders domestically from within the USA with full tracking on every order. Our about page and contact page are both live and accessible.
Consistent and Correct RUO Labeling and Content
The Amino Asylum and Paradigm Peptides cases both involved marketing practices that blurred the line between research compounds and consumer health products. Every product page, article, and communication from a compliant vendor must consistently maintain research use framing without making human benefit claims.
This is not a minor compliance detail. It is the legal foundation of the research peptide supply model. Fine Research Peptides maintains RUO compliance across all content and labeling. All compounds are labeled “For Research Use Only. Not for human or animal consumption.” For a full explanation of what RUO classification requires, see our RUO peptides guide.
No Criminal History or FDA Warning Letters
The Paradigm Peptides case is the clearest example of what this criterion addresses. A vendor with a history of FDA warning letters or enforcement actions has demonstrated that it operates in ways that attract regulatory scrutiny. This is a compounding risk factor, not a one-time mistake. Before ordering from any new vendor, searching the FDA warning letter database at FDA.gov for the vendor name is a basic due diligence step.
Peptide Calculator and Reconstitution Support
A vendor that provides practical research support tools demonstrates investment in the research community rather than pure product sales focus. Fine Research Peptides provides a free peptide calculator for reconstitution volume planning, a comprehensive peptide reconstitution guide, and a full research guide covering laboratory methodology, regulatory context, and compound reference information. These resources exist because we serve researchers, not just buyers.
The Peptide Sciences Alternative: What Displaced Researchers Are Looking For
Researchers who sourced from Peptide Sciences are specifically looking for a Peptide Sciences alternative that matches the quality documentation, domestic USA shipping, and compound range they relied on. Peptide Sciences generated an estimated $7.4 million per month before its March 2026 closure, which represents a significant pool of displaced research buyers actively evaluating alternatives.
The compounds most commonly sourced from Peptide Sciences that are available at Fine Research Peptides include BPC-157 and TB-500, both of which returned to FDA Category 1 compounding status in February 2026. Additional compounds include the BPC-TB Blend, Tirzepatide, Retatrutide, GHK-Cu, Tesamorelin, Epithalon, Semax, Selank, and NAD+.
All are independently third-party tested, correctly labeled, and shipped domestically from within the USA with tracking on every order.
Fine Research Peptides: A Compliant USA Research Peptide Supplier
Fine Research Peptides was not affected by the 2025 and 2026 enforcement wave because our operations have always been structured around the compliance requirements that the grey-market vendors ignored. Independent third-party testing on every batch. Consistent RUO labeling and content standards. Domestic USA shipping. No human benefit claims anywhere on the site.
The collapses of 2025 and 2026 have not changed how we operate. They have simply made what we already do more visible and more important to the research community.
Browse our complete shop for current compound availability and pricing. Our bestseller range covers the most ordered research peptides. For pricing across the full catalog, see our peptide pricing guide. For any pre-order questions, visit our FAQs or reach us through the contact page.
For guidance on verifying peptide quality before any purchase, see our companion article on how to verify research peptide quality.
Frequently Asked Questions
What is the best peptide company in the USA in 2026?
The best peptide company in the USA in 2026 is one that provides batch-specific independent third-party COA documentation, ships domestically with tracking, maintains consistent RUO labeling and content standards, has no history of FDA warning letters or enforcement actions, and provides transparent business contact information. Fine Research Peptides meets all of these criteria and supplies a comprehensive range of independently tested research compounds shipped from within the USA.
What happened to Peptide Sciences?
Peptide Sciences voluntarily shut down on March 6, 2026, posting a brief three-sentence notice and stopping orders without advance warning. No official explanation was provided beyond the word voluntary. The closure occurred against a backdrop of escalating FDA enforcement against the research peptide vendor market throughout 2025 and into 2026, including the June 2025 Amino Asylum warehouse raid and the December 2025 Paradigm Peptides guilty pleas.
What happened to Amino Asylum?
Amino Asylum was shut down following an FDA warehouse raid in June 2025. Federal agents seized inventory and records. The site went offline and has not reopened. The raid was part of a broader FDA enforcement escalation against research peptide vendors and represented the first physical raid on a major vendor in the sector.
What happened to Paradigm Peptides?
Paradigm Peptides’ founders Matthew Kawa and Jennifer Stechkober pleaded guilty to federal charges in December 2025. The investigation revealed that products labeled as SARMs contained testosterone, a Schedule III controlled substance. Matthew Kawa was sentenced to 70 months in federal prison and a $5 million forfeiture in July 2026. This was a criminal prosecution, not an administrative enforcement action.
Where can I buy research peptides after Peptide Sciences shut down?
Fine Research Peptides is a compliant USA-based research peptide supplier carrying a full range of compounds including BPC-157, TB-500, Tirzepatide, Retatrutide, GHK-Cu, Tesamorelin, Epithalon, Semax, Selank, and NAD+. All compounds are independently third-party tested with COA documentation available before ordering on our lab certifications page. All orders ship domestically from within the USA. Visit our shop for current availability.
How do I verify a research peptide supplier is legitimate?
Check for batch-specific independent third-party COA documentation, domestic USA shipping with trackable orders, consistent RUO labeling across all product pages and content, no FDA warning letters in the public FDA database, and transparent business contact information. See our full guide on how to verify research peptide quality for a complete evaluation framework.
Source Verified Research Peptides at Fine Research Peptides
Fine Research Peptides ships all research compounds domestically from within the USA with independent third-party COA documentation available before every purchase. Our operations are structured around the compliance standards that the research community deserves and that the enforcement events of 2025 and 2026 have made non-negotiable.
For additional context on the regulatory framework governing research peptides, see our are peptides illegal guide and RUO peptides guide. For educational resources across all research categories, visit our research guide.
For Research Purpose Only
All products referenced in this article are supplied by Fine Research Peptides strictly for laboratory and research use only. No compound is intended for human or animal consumption. Nothing in this article constitutes legal or regulatory advice. All factual statements about vendor shutdowns and enforcement actions are drawn from publicly available sources including court records, FDA public databases, and published industry reporting. Researchers are responsible for ensuring full compliance with all applicable local, state, and federal regulations governing the purchase, storage, and use of research compounds in their jurisdiction.


